Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
AssigneeAbbott Laboratories
InventorsA. Scott Muerhoff, Christopher Marohnic, Larry Birkenmeyer, John Prostko, Felisha Bogdan, Robin Gutierrez
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.
Claims47
A recombinant HCV NS3 antigen comprising a NS3 helicase sequence that comprises each of domains I, II and III of said helicase, wherein said antigen has increased immunoreactivity against HCV antibodies from test sample as compared to C33 antigen, wherein said recombinant HCV NS3 antigen comprises one or more of the characteristics selected from the group consisting of:
- diminished ATP-binding activity as compared to the ATP-binding activity of wild-type NS3 helicase
- diminished ATPase activity as compared to wild-type NS3 as compared to the ATP-binding activity of wild-type NS3 helicase, and
- increased redox stability as compared to the redox stability of wild-type NS3 helicase.
(canceled)
(canceled)
11-14. (canceled)
The recombinant HCV NS3 antigen of claim 11, wherein said antigen further comprises addition of at least one cysteine residue at the C-terminus end of said NS3 helicase.
(canceled)
(canceled)
20-21. (canceled)
(canceled)
(canceled)
27-29. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
46-47. (canceled)
50-51. (canceled)
A recombinant HCV NS3 antigen comprising a NS3 helicase sequence that comprises each of domains I, II and III of said helicase, wherein said antigen has increased immunoreactivity against HCV antibodies from serum as compared to C33 antigen, wherein said recombinant HCV NS3 antigen comprises increased redox stability as compared to the redox stability of wild-type NS3 helicase.
A recombinant HCV NS3 antigen comprising a NS3 helicase sequence that comprises each of domains I and II of said helicase, wherein said antigen has increased immunoreactivity against HCV antibodies from serum as compared to C33 antigen, and wherein said recombinant HCV NS3 antigen comprises increased redox stability as compared to the redox stability of wild-type NS3 helicase.
Dependencies are inferred from the claim text.